Recently, 16-alpha-18F-fluoro-17-beta-estradiol (FES) PET has been approved for clinical use in France and USA in recurrent or metastatic estrogen receptor (ER)-positive breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.